STAT4基因在肝病中的研究现状与进展

摘要/Abstract

摘要： 信号传导与转录激活因子（signal transducers and activators of transcription， STAT）是由Janus蛋白酪氨酸激酶（janus protein tyrosine kinase，JAK）活化的一类转录因子。STAT4是JAK/STAT信号通路中的一名重要成员。近年在各肝病的研究中发现，STAT4与各种肝病的发生与发展均有密切关系。本研究拟将近年对STAT4在各型肝病中的作用影响与相关研究作一综述，以期为找到更有效的缓解和治愈肝病的新方法提供新思路。

刘幸,撒亚莲. STAT4基因在肝病中的研究现状与进展[J]. .

LIU Xing and SA Yalian. Research Status and Progress of STAT4 Gene in Liver Diseases[J]. .

参考文献

[1] Warford WT,MoriguchiM,MorinobuA,et al.The biology of IL-12:coordinating innate and adaptive immune responses. Cytokine & Growth Factor Rev,2003,14(5):316-368.
[2]林莉，李小洁，魏晓丽．STAT4的作用机制及其在疾病中的相关研究[J]．细胞与分子免疫学杂志，2007，23(8):784—786。
[3]Nguyen KB，Wafford WT，Salomon R，et a1．Critical role for STAT4 activation by typel interferons in the interferon-gamma response to viral infection[J].Science，2002，297(5589)：2063—2066．
[4]Watford WT，Hissong BD，Bream JH，et a1．Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4[J].Immunol Rev,2004,202(2):139-156.
[5] Mendoza L.A network model for the control of the differentiation process in Th cells．Biosystems,2006,84(2):10l-114.
[6]Chitnis T，Najafian N，Benou C，et a1．Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis[J]．J Clin Invest，2001,108(5):739-747.
[7] Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 2006; 66: 11005-11012.
[8] Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol. 1998; 70: 83-243.
[9] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3: 133-146.
[10] Wang C, Zhang X, Zhu B, Hu D, Wu J, et al. Relationships between tumour necrosis factor-alpha, interleukin-12B and interleukin-10 gene polymorphisms and hepatitis B in Chinese Han haemodialysis patients. Nephrology (Carlton).2012;17: 167-174.
[11] Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, et al. Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms:pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther. 2011; 16: 1073-1080.
[12] Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 1997; 71: 3236-3243.
[13] Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology.2012; 56: 474-483.
[14] Miyagi T, Takehara T, Nishio K, Shimizu S, Kohga K, et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol. 2010; 53: 424-430.
[15] Liao Y, Cai B, Li Y, Chen J, Ying B, et al. Association of HLA-DP/DQ, STAT4 and IL-28B variants with HBV viral clearance in Tibetans and Uygurs in China. Liver Int. 2014.
[16] Rodriguez-Galan MC, Reynolds D, Correa SG, Iribarren P, Watanabe M, et al.Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J Immunol. 2009; 183: 740-748.
[17] Cho SS, Bacon CM, Sudarshan C, Rees RC, Finbloom D, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol. 1996; 157:4781-4789.
[18] Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, et al. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood. 2000; 96: 1844-1852.
[19] Shen XD, Ke B, Ji H, Gao F, Freitas MC, et al. Disruption of Type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism. Am J Transplant. 2012; 12:1730-1739.
[20] Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Pharmacogenet Genomics. 2012; 22: 784-795.
[21] Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics. 2012; 13: 735-738.
[22] Li N, Liu YH, Li SL, Fu CY, Zhou RR, et al. Protective role of synthetic oligodeoxynucleotides expressing immunosuppressive TTAGGG motifs in concanavalin A-induced hepatitis. Immunol Lett. 2013; 151: 54-60.
[23] Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology. 2003; 37: 296-303.
[24]Kato A, Graul-Layman A, Edwards MJ, Lentsch AB. Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4.Transplantation. 2002; 73: 1142-1145.
[25] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115: 209-218.
[26] Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;
134: 1655-1669.
[27] Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88: 125-172.
[28] Kong X, Horiguchi N, Mori M, Gao B. Cytokines and STATs in Liver Fibrosis.Front Physiol. 2012; 3: 69.
[29] Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7: 536-550.
[30] Avouac J, Furnrohr BG, Tomcik M, Palumbo K, Zerr P, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 2011; 63: 800-809.
[31] Cheng YL, Song WJ, Liu WQ, Lei JH, Kong Z, et al. The effects of interleukin (IL)-12 and IL-4 deficiency on worm development and granuloma formation in Schistosoma japonicum-infected mice. Parasitol Res. 2012; 110: 287-293.
[32] Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis. 2011; 31: 147-156.
[33] Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, et al. Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease. Transplantation. 2013; 95:203-208.
[34] Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, et al. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother. 2010; 59: 453-463.
[35] Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993; 178: 1223-1230.
[36] Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, et al.Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994; 153: 1697-1706.
[37] Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995; 7: 1135-1145.
[38] Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995; 55: 4404-4408.
[39] Harada N, Shimada M, Okano S, Suehiro T, Soejima Y, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2004; 173: 6635-6644.
[40] Liu L, Xu Y, Liu Z, Chen J, Zhang Y, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011; 128: 1692-1696.
[41] Wang Y, Feng D, Wang H, Xu MJ, Park O, et al. STAT4 Knockout Mice Are More Susceptible to Concanavalin A-Induced T-Cell Hepatitis. Am J Pathol.2014; 184: 1785-1794.
[42] Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996;87: 3877-3882.
[43] Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005; 6:722-729.
[44] Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007; 178: 7540-7549.
[45] Wang L, Jia D, Duan F, Sun Z, Liu X, et al. Combined anti-tumor effects of IFN-alpha and sorafenib on hepatocellular carcinoma in vitro and in vivo.Biochem Biophys Res Commun. 2012; 422: 687-692.
[46] Robertson MJ, Chang HC, Pelloso D, Kaplan MH. Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma. Blood. 2005; 106:963-970.
[47] Jiang DK, Sun J, Cao G, Liu Y, Lin D, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013; 45: 72-75.
[48]魏玉亮,樊方平,汤志亮,等.ICAM-1和STAT4在肝细胞癌中的表达及其侵袭转移的关系[J].江西医药,2017,52(6):573

快速检索引用检索图表检索高级检索